Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance
Frontiers in Genome Editing · 13.08.2026 · 8
DOI: 10.3389/fgeed.2026.1878460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Genome Editing, online erschienen am 13.08.2026. Verfasst von Shiqi Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, China. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chimeric antigen receptor T-cell therapy has changed the treatment landscape of relapsed or refractory hematological malignancies, but primary non-response and post-infusion relapse remain frequent clinical problems. In aggressive B-cell lymphomas, acute leukemias, and multiple myeloma, treatment failure is often driven by overlapping mechanisms rather than a single resistance pathway. These include antigen loss or reduced antigen density, impaired immune recognition, defective inflammatory signaling, checkpoint-mediated suppression, metabolic stress, and limited effector-cell persistence within suppressive disease niches. Main Body Genome engineering has become an important tool for both identifying and addressing these resistance mechanisms. CRISPR-based functional screening, single-cell perturbation approaches, and multi-omics profiling allow immune escape and tumor microenvironment-mediated resistance to be defined more functionally, rather than inferred only from correlative datasets. These insights can inform the design of CAR-T and CAR-NK therapies through multi-target or logic-gated receptors, checkpoint or exhaustion-pathway editing, cytokine-supported and armored constructs, metabolic fitness enhancement, and selected multiplex-editing strategies. In parallel, CAR-NK cells, universal allogeneic CAR-T products, and stem-cell-derived platforms may provide additional options in relapse-prone or heavily pretreated patients, particularly when autologous T-cell fitness, manufacturing feasibility, or repeat dosing is a concern.
Conclusion
A resistance-guided approach may help align engineered cellular therapy design with the dominant mechanisms of treatment failure in high-risk hematological malignancies. Rather than simply increasing engineering complexity, future CAR-T and CAR-NK development should link each modification to a measurable resistance mechanism, a feasible biomarker, and a clinically testable benefit. Prospective validation, genomic safety assessment, manufacturing consistency, and long-term monitoring will be essential before resistance-matched cellular immunotherapy can be broadly integrated into clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, China.
- School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Zitieren
APA
Cai, S., Tan, Y., Yang, Q., & Huang, J. (2026). Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance. Frontiers in Genome Editing, 8. https://doi.org/10.3389/fgeed.2026.1878460
Vancouver
Cai S, Tan Y, Yang Q, Huang J. Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance. Frontiers in Genome Editing. 2026;8. doi:10.3389/fgeed.2026.1878460
BibTeX
@article{Cai2026,
author = {Cai, Shiqi and Tan, Yang and Yang, Qian and Huang, Juan},
title = {Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance},
journal = {Frontiers in Genome Editing},
year = {2026},
volume = {8},
doi = {10.3389/fgeed.2026.1878460}
}
EUVIMED